Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
X Xiao, S Huang, S Chen, Y Wang, Q Sun… - Journal of Experimental & …, 2021 - Springer
Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and
transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell …
transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell …
Humoral immune mechanisms involved in protective and pathological immunity during COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 is
associated with excessive inflammation, as a main reason for severe condition and death …
associated with excessive inflammation, as a main reason for severe condition and death …
Cytokines in CAR T cell–associated neurotoxicity
Chimeric antigen receptor (CAR) T cells provide new therapeutic options for patients with
relapsed/refractory hematologic malignancies. However, neurotoxicity is a frequent, and …
relapsed/refractory hematologic malignancies. However, neurotoxicity is a frequent, and …
Critical care management of chimeric antigen receptor T‐cell therapy recipients
A Shimabukuro‐Vornhagen, B Böll… - CA: a Cancer …, 2022 - Wiley Online Library
Chimeric antigen receptor (CAR) T‐cell therapy is a promising immunotherapeutic treatment
concept that is changing the treatment approach to hematologic malignancies. The …
concept that is changing the treatment approach to hematologic malignancies. The …
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
AD Hughes, DT Teachey, C Diorio - Seminars in Immunopathology, 2024 - Springer
The advent of chimeric antigen receptor T cells (CAR-T) has been a paradigm shift in cancer
immunotherapeutics, with remarkable outcomes reported for a growing catalog of …
immunotherapeutics, with remarkable outcomes reported for a growing catalog of …
The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions
Y Li, Y Ming, R Fu, C Li, Y Wu, T Jiang, Z Li… - Frontiers in …, 2022 - frontiersin.org
Chimeric antigen receptor (CAR)-T cell therapy is effective in the treatment of
refractory/relapsed (r/r) hematological malignancies (r/r B-cell lymphoblastic leukemia, B-cell …
refractory/relapsed (r/r) hematological malignancies (r/r B-cell lymphoblastic leukemia, B-cell …
Can the cytokine adsorber CytoSorb® help to mitigate cytokine storm and reduce mortality in critically ill patients? A propensity score matching analysis
C Scharf, I Schroeder, M Paal, M Winkels… - Annals of intensive …, 2021 - Springer
Background A cytokine storm is life threatening for critically ill patients and is mainly caused
by sepsis or severe trauma. In combination with supportive therapy, the cytokine adsorber …
by sepsis or severe trauma. In combination with supportive therapy, the cytokine adsorber …
Blood purification with CytoSorb in critically ill COVID‐19 patients: a case series of 26 patients
Severe forms of the coronavirus disease 2019 (COVID‐19) can progress to sepsis‐like
complications accompanied by “cytokine storm” for which the most effective treatment has …
complications accompanied by “cytokine storm” for which the most effective treatment has …
Complications after CD19+ CAR T-cell therapy
O Penack, C Koenecke - Cancers, 2020 - mdpi.com
Simple Summary CD19+ Chimeric antigen receptor (CAR) T-cells are used against CD19+
hematologic malignancies, such as high-grade B-cell lymphoma and acute lymphoblastic …
hematologic malignancies, such as high-grade B-cell lymphoma and acute lymphoblastic …
The potential role of extracorporeal cytokine removal in hemodynamic stabilization in hyperinflammatory shock
Hemodynamic instability due to dysregulated host response is a life-threatening condition
requiring vasopressors and vital organ support. Hemoadsorption with Cytosorb has proven …
requiring vasopressors and vital organ support. Hemoadsorption with Cytosorb has proven …